Overview Dividends

(EHAB) Enhabit - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022

Home Health, Hospice, Therapy, Chronic Care, Palliative

EHAB EPS (Earnings per Share)

EPS Growth (3Y CAGR): -75.93%
EPS Trend (3Y Correlation): -42.1%

EHAB Revenue

Revenue Growth (3Y CAGR): 0.05%
Revenue Trend (3Y Correlation): -50.5%

Description: EHAB Enhabit October 24, 2025

Enhabit, Inc. (NYSE: EHAB) is a Dallas-based provider of home health and hospice services across the United States, offering a broad portfolio that includes skilled nursing, chronic disease management, therapy, and end-of-life care. The company rebranded from Encompass Health Home Health Holdings in March 2022 and has operated since 1998.

Key operational metrics (FY 2023) show revenue of roughly $1.1 billion, with a home-health segment contribution of about 68 % and a hospice contribution of 32 %. The firm reported an adjusted EBITDA margin near 7 %, reflecting the pressure of Medicare-centric reimbursement rates and the need for cost-efficient staffing models. Recent quarterly filings indicate a 4 % YoY increase in patient admissions, driven partly by the aging U.S. population and rising prevalence of chronic conditions such as diabetes and heart failure.

The home-health sector is currently expanding at a compound annual growth rate of 6-7 % (2022-2027), propelled by demographic trends, policy shifts favoring home-based care, and tighter hospital length-of-stay constraints. However, reimbursement uncertainty-particularly potential changes to Medicare’s Home Health Prospective Payment System-introduces upside/downside risk that Enhabit must navigate.

For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for benchmarking Enhabit against peers.

EHAB Stock Overview

Market Cap in USD	409m
Sub-Industry	Health Care Services
IPO / Inception	2022-07-01

EHAB Stock Ratings

Growth Rating	-33.0%
Fundamental	32.6%
Dividend Rating	-
Return 12m vs S&P 500	1.38%
Analyst Rating	3.40 of 5

EHAB Dividends

Currently no dividends paid

EHAB Growth Ratios

Growth Correlation 3m	72.5%
Growth Correlation 12m	7.4%
Growth Correlation 5y	-85.8%
CAGR 5y	-14.03%
CAGR/Max DD 3y (Calmar Ratio)	-0.24
CAGR/Mean DD 3y (Pain Ratio)	-0.39
Sharpe Ratio 12m	0.48
Alpha	-3.94
Beta	1.315
Volatility	53.51%
Current Volume	250.4k
Average Volume 20d	298.5k
Stop Loss	7.9 (-5.5%)
Signal	-0.87

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-133.2m TTM) > 0 and > 6% of Revenue (6% = 62.3m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 1.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.19% (prev 6.40%; Δ 0.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 52.8m > Net Income -133.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.4m) change vs 12m ago 2.59% (target <= -2.0% for YES)

Gross Margin 48.33% (prev 46.58%; Δ 1.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 78.49% (prev 73.42%; Δ 5.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.24 (EBITDA TTM -59.2m / Interest Expense TTM 39.0m) >= 6 (WARN >= 3)

Altman Z'' 0.48

(A) 0.06 = (Total Current Assets 205.5m - Total Current Liabilities 130.9m) / Total Assets 1.23b

(B) 0.10 = Retained Earnings (Balance) 121.3m / Total Assets 1.23b

(D) 0.19 = Book Value of Equity 121.8m / Total Liabilities 642.5m

Total Rating: 0.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.58

1. Piotroski 5.0pt = 0.0

2. FCF Yield 5.46% = 2.73

3. FCF Margin 4.75% = 1.19

4. Debt/Equity 0.96 = 2.05

5. Debt/Ebitda -8.34 = -2.50

6. ROIC - WACC (= -11.30)% = -12.50

7. RoE -24.38% = -2.50

8. Rev. Trend -50.52% = -3.79

9. EPS Trend -42.11% = -2.11

What is the price of EHAB shares?

As of October 24, 2025, the stock is trading at USD 8.36 with a total of 250,350 shares traded.
Over the past week, the price has changed by +4.37%, over one month by +3.59%, over three months by +20.81% and over the past year by +19.26%.

Is Enhabit a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Enhabit (NYSE:EHAB) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.58 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EHAB is around 7.92 USD . This means that EHAB is currently overvalued and has a potential downside of -5.26%.

Is EHAB a buy, sell or hold?

Enhabit has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold EHAB.

Strong Buy: 1
Buy: 0
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EHAB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	9.4	12.2%
Analysts Target Price	9.4	12.2%
ValueRay Target Price	8.6	2.6%

EHAB Fundamental Data Overview October 20, 2025

Market Cap USD = 408.6m (408.6m USD * 1.0 USD.USD)
P/E Forward = 16.3399
P/S = 0.3937
P/B = 0.7424
Beta = 1.315
Revenue TTM = 1.04b USD
EBIT TTM = -87.3m USD
EBITDA TTM = -59.2m USD
Long Term Debt = 456.9m USD (from longTermDebt, last quarter)
Short Term Debt = 48.2m USD (from shortTermDebt, last quarter)
Debt = 532.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 493.9m USD (from netDebt column, last quarter)
Enterprise Value = 902.5m USD (408.6m + Debt 532.8m - CCE 38.9m)
Interest Coverage Ratio = -2.24 (Ebit TTM -87.3m / Interest Expense TTM 39.0m)
FCF Yield = 5.46% (FCF TTM 49.3m / Enterprise Value 902.5m)
FCF Margin = 4.75% (FCF TTM 49.3m / Revenue TTM 1.04b)
Net Margin = -12.83% (Net Income TTM -133.2m / Revenue TTM 1.04b)
Gross Margin = 48.33% ((Revenue TTM 1.04b - Cost of Revenue TTM 536.2m) / Revenue TTM)
Gross Margin QoQ = 46.94% (prev 49.90%)
Tobins Q-Ratio = 0.74 (Enterprise Value 902.5m / Total Assets 1.23b)
Interest Expense / Debt = 1.63% (Interest Expense 8.70m / Debt 532.8m)
Taxrate = 28.75% (2.30m / 8.00m)
NOPAT = -62.2m (EBIT -87.3m * (1 - 28.75%)) [loss with tax shield]
Current Ratio = 1.57 (Total Current Assets 205.5m / Total Current Liabilities 130.9m)
Debt / Equity = 0.96 (Debt 532.8m / totalStockholderEquity, last quarter 552.4m)
Debt / EBITDA = -8.34 (negative EBITDA) (Net Debt 493.9m / EBITDA -59.2m)
Debt / FCF = 10.02 (Net Debt 493.9m / FCF TTM 49.3m)
Total Stockholder Equity = 546.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.87% (Net Income -133.2m / Total Assets 1.23b)
RoE = -24.38% (Net Income TTM -133.2m / Total Stockholder Equity 546.3m)
RoCE = -8.70% (EBIT -87.3m / Capital Employed (Equity 546.3m + L.T.Debt 456.9m))
RoIC = -5.93% (negative operating profit) (NOPAT -62.2m / Invested Capital 1.05b)
WACC = 5.37% (E(408.6m)/V(941.4m) * Re(10.86%) + D(532.8m)/V(941.4m) * Rd(1.63%) * (1-Tc(0.29)))
Discount Rate = 10.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.39%
[DCF Debug] Terminal Value 65.38% ; FCFE base≈41.5m ; Y1≈35.3m ; Y5≈27.2m
Fair Price DCF = 6.43 (DCF Value 326.1m / Shares Outstanding 50.7m; 5y FCF grow -17.93% → 3.0% )
EPS Correlation: -42.11 | EPS CAGR: -75.93% | SUE: -4.0 | # QB: 0
Revenue Correlation: -50.52 | Revenue CAGR: 0.05% | SUE: 0.64 | # QB: 0

Additional Sources for EHAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle